A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Public ClinicalTrials.gov record NCT07223138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Study identification
- NCT ID
- NCT07223138
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,560 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2025 (Actual)
- Primary completion
- Feb 4, 2028 (Estimated)
- Completion
- Feb 4, 2028 (Estimated)
- Last update posted
- Sep 9, 2026
2025 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | Avondale | Arizona | 85392 | — |
| Clinical Site | Mesa | Arizona | 85210 | — |
| Clinical Site | Phoenix | Arizona | 85032 | — |
| Clinical Site | Scottsdale | Arizona | 85260 | — |
| Clinical Site | Tucson | Arizona | 85748 | — |
| Clinical Site | Jonesboro | Arkansas | 72401 | — |
| Clinical Site | Upland | California | 91786 | — |
| Clinical Site | Avon Park | Florida | 33825 | — |
| Clinical Site | Clearwater | Florida | 33765 | — |
| Clinical Site | Tampa | Florida | 33607 | — |
| Clinical Site | Charlotte | North Carolina | 28262 | — |
| Clinical Site | Leland | North Carolina | 28451 | — |
| Clinical Site | Middleburg Heights | Ohio | 44130 | — |
| Clinical Site | Duncansville | Pennsylvania | 16635 | — |
| Clinical Site | Memphis | Tennessee | 38119 | — |
| Clinical Site | Baytown | Texas | 77521 | — |
| Clinical Site | Lubbock | Texas | 79424 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07223138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07223138 live on ClinicalTrials.gov.